Full-Time
Associate Software Engineer 1
Posted on 8/12/2026
AbbVie
10,001+ employees
Global biopharmaceutical company developing medicines
Compensation Overview
$58.7k - $103.5k/yr
North Chicago, IL, USA
Hybrid
Bachelor's
 Software Engineering (1) |
|---|
Get referred to AbbVie
See people who can refer or advise you
- A bachelor's degree is required, with zero years of experience.
- Theoretical and practical knowledge sufficient to carry out the job functions is required.
- Experience with one or more programming languages, such as Python, Java, or .NET, is required.
- Perform analyses and implement software solutions to deliver precise, reliable, and reproducible products in a timely manner under the direction of a more senior leader.
- Follow established technical protocols and assess results with supervision while performing routine tasks competently and organizing work effectively.
- Recognize and report data or technical variances.
- Learn and effectively implement new methods and technologies.
- Consult literature and publicly available information to understand the purpose of assignments.
- Obtain vendor estimates and quotes and provide them as input into overall project time and cost estimates.
- Produce and maintain required technical documentation associated with work products.
- Understand and adhere to corporate and divisional standards, including the code of conduct, safety, GxP compliance, data security, and the software development lifecycle.
- IT internship or co-op experience in the manufacturing or pharmaceutical industry is desirable.
- Hands-on project or practice experience utilizing agentic workflows, large language models, and other automations is preferred.
- Experience using tools such as Git is preferred.
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Get referred to AbbVie
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 10.2% to $16.99 billion, beating estimates and guidance.
- AbbVie raised 2026 sales guidance to about $67.6 billion after Q2 momentum.
- Skyrizi reached $5.5 billion in Q2 2026, supporting $21.7 billion full-year guidance.
What critics are saying
- Epcoritamab missed its July 23, 2026 phase 3 overall-survival endpoint in DLBCL.
- Skyrizi will represent nearly one-third of 2026 revenue, concentrating AbbVie’s fate.
- Skyrizi and Rinvoq face 2033-plus patent cliffs; Humira’s collapse shows the script.
What makes AbbVie unique
- AbbVie’s 2026 growth engine is Skyrizi and Rinvoq, both up 24% in Q2.
- AbbVie converts immunology scale into 34.8% five-year free-cash-flow margins.
- AbbVie bought Apogee on June 22, 2026 to deepen its inflammatory-disease pipeline.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Flexible Work Hours
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 3%1 year growth
↑ 3%2 year growth
↑ 3%AbbVie stock has returned 24.5% over the past three months, trading near its 52-week high. The pharmaceutical company's growth hinges on a pending regulatory decision for SKYRIZI, an immunology treatment that generates nearly a third of guided revenue. SKYRIZI sold $5.5 billion in Q2 2026, up 24% operationally. AbbVie guides the drug to $21.7 billion for 2026 against total company revenue of approximately $67.6 billion. The company has raised its 2026 guidance twice by $600 million combined. A subcutaneous induction option for Crohn's disease awaits regulatory approval this fall. Management expects the new dosing method to meaningfully accelerate SKYRIZI sales, though the commercial impact won't materialise until early 2027 due to contract timelines. Clinical trial results showed endoscopic response and remission rates 25 points above placebo.
AbbVie, the biopharmaceutical company spun off from Abbott Laboratories in 2013, has risen 9.7% to $249.64 per share over the past six months. The company generates $64.39 billion in revenue over the past 12 months, benefiting from significant economies of scale in its operations. AbbVie's free cash flow margin averaged 34.8% over the last five years, amongst the best in the healthcare sector. This strong cash generation enables reinvestment and capital returns to investors. However, the company's five-year annualised revenue growth of 3.7% remains tepid compared to sector peers. Despite this weakness, AbbVie's shares trade at 16.3 times forward price-to-earnings ratio. The company develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.
Genmab and AbbVie confirmed on 23 July that their jointly developed bispecific antibody epcoritamab failed to meet its primary endpoint in a Phase 3 trial. The study evaluated epcoritamab monotherapy against chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma. In the US, where overall survival was the sole primary endpoint, the trial did not demonstrate statistically significant improvement. Despite the setback, epcoritamab maintains its accelerated FDA approval. Both companies will review the full data set with regulators to determine next steps. Genmab reported H1 2026 revenue of $2.051 billion, up 25% year-over-year, raising full-year guidance to $4.325–$4.525 billion. AbbVie posted Q2 2026 net revenues of $16.99 billion, up 10.2%, driven by its immunology portfolio generating $8.79 billion.
AbbVie's strong operational performance has not translated into stock gains matching its pharmaceutical peers. The drugmaker achieved 10.4% revenue growth and a 34% operating margin over the past year, ranking second among six key competitors. Despite these results, AbbVie's stock returned 30% over twelve months, trailing Merck's 67% and Johnson & Johnson's 54%. The disconnect appears rooted in market concerns about future competition. Analysts questioned management about competitive dynamics for key immunology drugs SKYRIZI and RINVOQ, which each grew sales 24%. The company trades at 70.1 times earnings but lacks the premium stock performance of peers. The market seems to be pricing in risks that AbbVie's high-performing drugs will face tougher competition, potentially eroding current growth rates and margins.
Why Bristol Myers Squibb is investing $2.3bn in Texas. August 12, 2026 Bristol Myers Squibb is investing US$2.3bn in a new manufacturing facility in Houston, Texas, aiming to reinforce the US's pharmaceutical supply chain Bristol Myers Squibb (BMS) says it will invest US$2.3bn into a new manufacturing hub in Houston, Texas to boost its domestic pharmaceutical supply chain. The plan is part of the company's five year commitment to invest US$40bn in the US across research and development, domestic manufacturing and technology. Christopher Boerner, CEO of BMS, says: "As part of our US$40bn commitment to the United States, we're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs." What will the investment create? BMS says its new hub will allow the company to manufacture multiple types of medicine including small molecules, biologics and antibody drug conjugates. The campus will be located at Generation Park, spanning across 600,000 square feet, and aims to initially create around 500 skilled jobs. Building this new facility will allow the company to manufacture multiple types of medicine including small molecules, biologics and antibody drug conjugates. Initial plans are expected to bring construction between 2027 and 2030, during which BMS is expecting to create around 2,000 construction and other indirect jobs. BMS currently has seven manufacturing and commercial manufacturing facilities across the world. US pharmaceutical supply chain. According to research from the US Pharmacopeia in 2024, more than 50% of active pharmaceutical ingredient (API) production comes from Europe and India, while the US accounts for just 12%. The new BMS facility is expected to lower reliance on overseas production and develop the US supply chain. US Secretary of Commerce Howard Lutnick says: "Bristol Myers Squibb's US$2.3bn investment in Texas will create hundreds of high-paying jobs and strengthen our pharmaceutical supply chains, ensuring America is never reliant on foreign sources for critical medicines." In January 2026, Abbvie committed US$100bn towards domestic research, development and capital investments over a 10 year period. This funding has already seen some allocations, including across two API plants in Illinois, and another US$1.4bn for a manufacturing campus focusing on immunology, neuroscience and oncology products in North Carolina. Abbvie has also acquired a manufacturing facility in Arizona, where it designated US$175m to expand capacity for drug delivery devices. Company Portals